Lightnews — Scholar-powered news

Matthias Guckenberger @mguckenberger.bsky.social · May 25

Fresh from #ASCO2025
meetings.asco.org/abstracts-pr...
SBRT vs microwave ablation (MWA) in pts with CRC liver oligo-mets
➡️ n=100, n=92 treated (39 SBRT, 53 MWA)
➡️ 18/92 pts (20%) reported side effects
➡️ n=3 G3-4 pain; n=2 infections after open MWA, n=1 bowelperforation after percutaneous MWA

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

1 2 1

Matthias Guckenberger @mguckenberger.bsky.social · May 25

Neoadjuvant chemo-IO for Borderline Resectable & Unresectable Stage III NSCLC

Conclusion of authors: "high rates of surgical resectability"

Pts with completed surgery:
III A: 65/79 - 82%
III B: 16/27 - 59%
III C: 3/6 - 50%

-> careful interpretation needed

jamanetwork.com/journals/jam...

PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer

This cohort study evaluates the efficacy of neoadjuvant programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) blockade combined with chemotherapy in enhancing surgical out...

jamanetwork.com

2 2

Matthias Guckenberger @mguckenberger.bsky.social · Jan 27

🔥 SAVE THE DATE 🔥

❓ What is the population-health effect of novel anti-cancer drugs
❓ How do anti-cancer drugs compare to other drugs and health services
❓ How to improve sustainability of cancer care and medicine in the future

Virtual Grand Rounds in Radiation Oncology
www.usz.ch/veranstaltun...

1 3 6

Matthias Guckenberger @mguckenberger.bsky.social · Jan 5

Thought provoking !
Population-health impact of new drugs recommended by NICE in England during 2000–20
- quality-adjusted life-years and incremental cost-effectiveness ratio used for analysis
👉 overall NEGATIVE (!) cumulative impact
👉 data for #radonc ?
www.thelancet.com/journals/lan...

2 1 11

Matthias Guckenberger @mguckenberger.bsky.social · Jan 5

Retrospective multicenter study of SBRT for pulmonary oligometastatic HNSCC
- 16 centers, 178 pts, 284 pulmonary mets
- 1a local failure rate 5.5%
- no grade 4/5 toxicities
👉 supporting prospective evaluation, in preparation by
EORTC & P Balermpas
www.redjournal.org/article/S036...

DEFINE_ME

www.redjournal.org

2

Matthias Guckenberger @mguckenberger.bsky.social · Jan 2

Aiming to refine your #radonc in 2025 !

Offer RT for low-volume metastatic PC, only ?
What benefit of RT is to be communicated to pts & colleagues ?
How about SBRT or surgery ?

Virtual Grand Rounds in Radiation Oncology

Jan 8th / 17:00 - 17:30 CET
Dr Alberto Bossi

👇
www.usz.ch/veranstaltun...

2 11

Matthias Guckenberger @mguckenberger.bsky.social · Dec 24

Virtual Grand Rounds in Radiation Oncology

Let`s start 2025 with another highly-important lecture

Jan 8th 2025 - 17:00 - 17:30
Dr. Alberto Bossi

Radiotherapy of the primary in metastatic prostate cancer - insights from PEACE-1

Link 👇
www.usz.ch/veranstaltun...

1

Matthias Guckenberger @mguckenberger.bsky.social · Dec 23

Season's Greetings

3

Matthias Guckenberger @mguckenberger.bsky.social · Dec 19

Safe practice of spine SBRT requires high-quality data about SC dose tolerance
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...

Radiation Myelitis After Hypofractionated Spine Stereotactic Body Radiation Therapy

This cohort study characterizes the risk of radiation myelitis after spine stereotactic body radiation therapy to update the current dosimetric constraints.

jamanetwork.com

2 6

Matthias Guckenberger @mguckenberger.bsky.social · Dec 19

Todas is HCC day!
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma

This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.

jamanetwork.com

2 3

Matthias Guckenberger @mguckenberger.bsky.social · Dec 19

And yet another prospective trial confirming excellent efficacy of SBRT for localized HCC
- n=36 pts
- median tumor size 2.3 cm
- median FU 49 mo
- 3-year local control rate 93%
- Grade 3 AE 11%
www.redjournal.org/article/S036...

2 2

Matthias Guckenberger @mguckenberger.bsky.social · Dec 19

Randomized comparison of SBRT vs RFA for recurrent small HCC (n=166 pts)
👆 Freedom from local progression significantly improved after SBRT: 2a 92.7% vs 75.8%, HR=0.45 !
👉 No difference in PFS (median 37.6 vs 27.6mo) and OS (2a 97.6% vs 93.9%)
👍
ascopubs.org/doi/10.1200/...

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial

PURPOSETo assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC).METHODSIn this trial, ...

ascopubs.org

1 2 5

Matthias Guckenberger @mguckenberger.bsky.social · Dec 15

Remember the misleading press about "brutal" #radonc after PROSPECT ?

This is what modern RT can achieve for elderly breast cancer patients !
👉 "Endocrine Tx was associated with a greater reduction in HRQOL compared with RT at 24 mo"
👉 oncological data awaited

www.thelancet.com/journals/lan...

1 6 14

Matthias Guckenberger @mguckenberger.bsky.social · Dec 15

ESTRO power team !

Anna Kirby and Barbara Jereczek-Fossa as past-president and president-elect

Thanks you so much for your 💪 collaboration, friendship and dedication, to
👉 advance multidisciplinary cancer care
👉 elevate radiation oncology
👉 develop ESTRO society

1 4

Matthias Guckenberger @mguckenberger.bsky.social · Dec 7

Radiation Oncology is characterized by rapid innovation

Dissemination & implementation are important aspects to bring this progress to our cancer patients in daily practice

Well written review by Erin Gillespie and colleagues 👇
www.redjournal.org/article/S036...

DEFINE_ME

www.redjournal.org

2 13

Matthias Guckenberger @mguckenberger.bsky.social · Dec 5

In case you may have missed any of the

Virtual Grand Rounds in Radiation Oncology lectures

Recordings are 👇
youtube.com/playlist?lis...

Endorsed by:
ESTRO
DEGRO
SASRO

1 8 23

Matthias Guckenberger @mguckenberger.bsky.social · Nov 28

Virtual Grand Rounds in Radiation Oncology

„Revving Up Gastric Cancer Care: Insights from the TOPGEAR Trial”

Presented by Prof. Karin Haustermans

December 4th 17:00 – 17:30

Link to online meeting 👇
www.usz.ch/veranstaltun...

Endorsed by:
ESTRO
DEGRO
SASRO

3 9

Matthias Guckenberger @mguckenberger.bsky.social · Nov 27

Thanks Wendy !

1 2

Matthias Guckenberger @mguckenberger.bsky.social · Nov 27

What is the value of the rectal spacer considring excellent outcome of PACE-B ?

For dose escalation protocols in higher risk pts only ?

1 1

Matthias Guckenberger @mguckenberger.bsky.social · Nov 27

ESTRO Scientific Council Meeting in Brussels

Hopefully in brighter colors than todays sky …

5

Matthias Guckenberger @mguckenberger.bsky.social · Nov 26

ETH Zürich Polyball

Zwischen Göttern und Menschen

Preparations almost finished

2

Reposted by Matthias Guckenberger

Chris Parker @ccparker.bsky.social · Nov 25

PEACE-1 trial of prostate radiotherapy in mHSPC. Improvement in rPFS when used in addition to ADT and abiraterone. Medsky. Oncsky.

1 9 26

Matthias Guckenberger @mguckenberger.bsky.social · Nov 26

PEACE-1 published
Radiotherapy of the prostate in metastatic pts prevents serious GU complications, in pts with low and high tumor burden

How to select patients?
- all ?
- based on live expectancy ?
- response to systemic Tx ?
- prostate volume ?

www.thelancet.com/journals/lan...

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Combining radiotherapy with standard of care plus abiraterone improves radiographic progression-free survival and castration resistance-free survival, but not overall survival in patients with low-vol...

www.thelancet.com

6 11

Matthias Guckenberger @mguckenberger.bsky.social · Nov 26

Curious about #RadiationOncology on BlueSky
Warm welcome to all colleagues and friends !

1 9